SimianX AI LogoSimianX AI

Asset profile

NGN-401 · Neurogene (NGNE)

Indication
Rett syndrome
Also known as
EXACT
CompanyNGNENeurogene

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning…

Start live analysis of NGNERun 8-agent AI analysis

On the calendar

Timeline

Newest first.

Oct 27, 2026
11:30 AM
NGNENeurogene

Neurogene presents new NGN-401 preclinical data at ESGCT 2026 Congress

Conference presentationCompany press release
Oct 20, 2026
11:30 AM
NGNENeurogene

Neurogene to present NGN-401 preclinical and clinical data at ESGCT 2026

Conference presentationCompany press release
Jun 29, 2026
12:00 PM
NGNENeurogene

Neurogene reports positive Phase 1/2 data for NGN-401 in Rett syndrome

Topline resultsSEC 8-KOpen record2 updates
Jun 8, 2026
11:32 AM
NGNENeurogene

Neurogene June 2026 Corporate Presentation: NGN-401 milestones

Conference presentationSEC 8-K
Mar 24, 2026
11:31 AM
NGNENeurogene

Neurogene: Embolden registrational trial 100% enrolled; dosing completion 2Q 2026

Trial registry changeSEC 8-K
Feb 26, 2026
09:02 PM
NGNENeurogene

Neurogene NGN-401 receives FDA Breakthrough Therapy Designation

FDA designationSEC 8-K

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT05898620Phase 3Active, not recruitingDec 1, 20293313 of 16 sites in the United States
NGN-401 · Neurogene (NGNE) — FDA Timeline & Readiness Checklist | SimianX AI